Capricor Therapeutics, Inc. (CAPR)
| Market Cap | 109.19M |
| Revenue (ttm) | 474,520 |
| Net Income (ttm) | -10.95M |
| Shares Out | 19.80M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $5.34 |
| Previous Close | $5.06 |
| Change ($) | 0.28 |
| Change (%) | 5.53% |
| Day's Open | 5.10 |
| Day's Range | 4.62 - 5.39 |
| Day's Volume | 517,203 |
| 52-Week Range | 0.88 - 12.32 |
-Technology Licensed from Johns Hopkins University-
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-
—Capricor to leverage Lonza's expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply—
Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19 Trial Assessing Ability of Capricor's Cardiac Cell Therapy, C...
- Data Expected Second Quarter 2021 -
Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript
Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- - Novel Vaccine Induce d Long-Lasting Immunity to Multiple SARS-CoV-2 Protei...
Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins
Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET
--Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage bi...
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell ...
Capricor Therapeutics (NASDAQ: CAPR) shares are trading higher on Tuesday after the company announced the U.S.
– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 –
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2020 Results - Earnings Call Transcript
Exosome Platform for COVID-19 -Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies- -Preclinical Data Shows Positive Antibody Response-
Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor Therapeutics Inc. (CAPR) CEO Linda Marban on Q1 2020 Results - Earnings Call Transcript
Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Duchenne Muscular Dystrophy Program -Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Lim...
Capricor Therapeutics Inc.’s (NASDAQ: CAPR) shares soared after data that pointed to a 100 percent survival rate in critical COVID-19 patients treated with new CAP-1002 cardiac cell therapy wa...
U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients
LOS ANGELES, April 03, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutic...
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
Capricor Therapeutics' (CAPR) CEO Linda Marban on Q4 2019 Results - Earnings Call Transcript
Company Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program Company Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program
Is (CAPR) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for February 3rd
Top Ranked Momentum Stocks to Buy for January 28th
LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological ther...
LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological ther...
Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q3 2019 Results - Earnings Call Transcript
Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Call Scheduled for Thursday, October 24th at 10:30am Eastern Time
--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies-- --Company to Host Conference Call Today at 5:30 AM PT / 8:30...
Capricor Therapeutics shares CAPR, -0.32% rose 3.6% in premarket trade Tuesday, after the clinical-stage biotech said the U.s.
Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies Company Exploring Potential for Accelerated Approval under RMAT Des...
Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation
LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeu...
Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q2 2019 Results - Earnings Call Transcript
Capricor (CAPR) delivered earnings and revenue surprises of 26.25% and 86.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor announced positive interim results from its phase 2 HOPE-2 study using CAP-1002 to treat patients with Duchenne muscular dystrophy.
Capricor Therapeutics news about the results from a recent clinical trial for its CAP-1002 therapy has CAPR stock soaring Monday. The post Capricor Therapeutics News: Why CAPR Stock Is Skyrock...
Capricor Therapeutics Inc. shares more than doubled on Monday after the firm announced interim analysis for its Duchenne muscular dystrophy (DMD) midstage trial.
Shares of Capricor Therapeutics Inc. nearly doubled (up 93%) in very active premarket trading Monday, after the biotechnology company announced upbeat results from a trial for its treatment (C...
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q1 2019 Results - Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q4 2018 Results - Earnings Call Transcript
About CAPR
Capricor Therapeutics, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatme... [Read more...]
| Industry Biotechnology | Founded 2005 |
| CEO Linda Marban | Employees 16 |
| Stock Exchange NASDAQ | Ticker Symbol CAPR |
Financial Performance
In 2019, CAPR's revenue was $1.01 million, a decrease of -39.87% compared to the previous year's $1.67 million. Losses were -$7.64 million, -49.70% less than in 2018.
Analyst Forecasts
According to one analyst, the rating for CAPR stock is "Buy" and the 12-month stock price forecast is 12.00.